A GABRIEL Consortium Large-Scale Genome-Wide Association Study of Asthma

 

 

 

RESTRICTED

Study Description

European cases and population-matched controls were obtained from clinics and cohort and cross-sectional population surveys. We included some family-based studies, cases and controls from our first-generation genome-wide association study, and cases and controls of European descent from Canadian, Australian and US surveys. Asthma was considered present if diagnosed by a physician. We defined childhood-onset asthma as being present below the age of 16 years and adult-onset asthma to have started at 16 years or older. Some surveys contributed samples to both age-of-onset groups. Other subgroups were made up of cases of unknown age of onset, cases with occupational asthma or cases of severe asthma. All participants or their parents provided signed informed consent to participate in the study, according to the rules of local ethics committee. After quality control and filtering, we retained genotype on 582,892 SNPs on 10,365 cases and 16,110 controls from 23 different studies as described in the Table below. 1


[Download PDF]
 
  Cases Controles
Study
(Known age of onset)
Country Total Childhood-onset
(% male)
Later-onset
(% male)
Total For childhood-onset
(% male)
For later-onset
(% male)
ALSPAC UK 607 607 (57%) - - 609 609 (51%) - -
B58C UK 445 213 (56%) 232 (38%) 420 200 (44%) 220 (50%)
BAMSE Sweden 239 239 (63%) - - 246 246 (48%) - -
BUSSELTON Australia 398 188 (51%) 210 (33%) 809 390 (45%) 419 (41%)
CAPPS & SAGE Canada 88 88 (66%) - - 182 182 (51%) - -
ECRHS Multicentre 664 279 (56%) 385 (34%) 1546 620 (50%) 926 (50%)
EGEA France 676 482 (61%) 194 (49%) 1252 598 (48%) 654 (48%)
GABRIEL ADVANCED
SURVEYS
Germany 841 841 (63%) - - 851 851 (52%) - -
GAIN Multicentre 1475 1475 (56%) - - 1668 1668 (50%) - -
KARELIA ALLERGY
STUDY
Finland 73 33 (61%) 40 (0%) 75 36 (61%) 39 (0%)
KMSU Russia 291 112 (66%) 179 (39%) 277 116 (47%) 161 (52%)
MAGICS Germany 630 630 (67%) - - 572 572 (50%) - -
MAS Germany 171 171 (57%) - - - - - - -
MRCA-UKC UK 177 177 (62%) - - 399 399 (29%) - -
PIAMA Holland 172 172 (59%) - - 187 187 (46%) - -
SALPADIA Switzerland 608 237 (62%) 371 (39%) 913 356 (52%) 557 (50%)
SLSJ FAMILIAL
COLLECTION
Canada 586 373 (50%) 213 (34%) 613 390 (49%) 223 (43%)
TOMSK Russia 259 197 (65%) 62 (29%) 422 91 (56%) 331 (52%)
UFA Russia 330 269 (67%) 61 (41%) 348 209 (49%) 139 (78%)
TOTAL   8730 6783   1947   11389 7720   3669  

 

Study (Unnown age of onset) Total cases(% males) Total controls(% males)
CAPPS & SAGE Canada 179 (46%)   372 (48%)  
OCCUPATIONAL Multicentre 529 (83%)   698 (85%)  
AUGOSA UK 637   (48%) 2677   (67%)
SEVERE UK 290 (39%)   974 (49%)  
TOTAL   1635     4721    
   

  _________________
  1The individuals included in the NEJM publication are a subset of the CAPPS and SAGE populations.